BIOMEDICAL ENGINEERING-APPLICATIONS BASIS COMMUNICATIONS, cilt.19, sa.1, ss.37-46, 2007 (SCI-Expanded)
It is assumed that bosentan, a non-selective ET-1 receptor antagonist, will enhance fracture healing. The aim of this prospective randomized controlled study was to investigate the effects of transcutaneous bosentan administration into diaphyseal bone fractures using radiology, histology, prostaglandin E-2 (PGE(2)) and leukotrien C-4 (LTC4) activity measurements.